New SARS-CoV-2 Variant PJ.2.1: Vaccine Antibodies Provide Protection
en-GBde-DEes-ESfr-FR

New SARS-CoV-2 Variant PJ.2.1: Vaccine Antibodies Provide Protection


Germany’s COVID-19 traffic light is on red (https://corona-ampel.de/), and the number of infections is high. But how well is the population protected against the virus variants currently circulating? The new SARS-CoV-2 variant PJ.2.1 has been spreading since May and has long since reached Europe. It traces back to an older viral lineage that has since largely disappeared from the infection landscape. However, the virus likely persisted in a person with a long-term infection and underwent significant changes through numerous mutations. Researchers from the Infection Biology Unit at the German Primate Center – Leibniz Institute for Primate Research, in collaboration with colleagues from Hannover Medical School, investigated how efficiently PJ.2.1 can penetrate human cells and how well antibodies from vaccinated individuals neutralize the new variant. The results show that PJ.2.1 binds more strongly than the other virus variants studied to the ACE2 receptor, which serves as the entry point for SARS-CoV-2 into human cells, and enters certain cells that produce only small amounts of ACE2 more effectively. Despite these changes, the new variant was effectively neutralized by antibodies produced following vaccination with the current booster vaccine, which has been adapted to the XFG variant. The results suggest that vaccination provides protection against PJ.2.1. However, this could change if the variant acquires additional mutations that enable it to evade the immune response (Journal of Infection, The Lancet Infectious Diseases).

A hallmark of SARS-CoV-2 is the continuous emergence of new viral variants with changes in the spike protein, which allow the virus to partially evade the antibody response. Often, such variants differ from their predecessors by only a few mutations in the spike protein. These can alter binding sites for antibodies and/or influence binding to the ACE2 receptor, which the virus uses to enter human cells. In addition, however, variants may also emerge that are characterized by an unusually large number of mutations - particularly in the spike protein - and thus evade the existing antibody response particularly efficiently. Such so-called saltation variants can develop during long-term infections. In this process, the virus has the opportunity over an extended period to replicate within the body of an infected person and gradually undergo significant changes.

Since May 2026, a new saltation variant of SARS-CoV-2 has been spreading: PJ.2.1. The variant was first detected in Canada and subsequently spread to the United States. Until now, it was unclear how efficiently PJ.2.1 can penetrate cells and how susceptible the variant is to neutralizing antibodies. In particular, it was not known how effectively antibodies produced following vaccination can inhibit PJ.2.1.

A research team led by infection biologists Markus Hoffmann and Stefan Pöhlmann from the German Primate Center – Leibniz Institute for Primate Research, in collaboration with Georg Behrens’s research group at Hannover Medical School, investigated these questions. Their findings show that PJ.2.1 is spreading rapidly in Canada, the U.S., and Spain; its prevalence is also rising in the Netherlands and France. A spread in Germany is therefore to be expected. With infection rates remaining high overall, the variant has been detected in all age groups. There is currently no evidence of more severe disease progression or new symptoms compared to other SARS-CoV-2 variants.

The researchers found that the spike protein of PJ.2.1 binds more strongly to ACE2. Consistent with this, PJ.2.1 was better able than other variants to penetrate cells that produce only small amounts of the ACE2 receptor. PJ.2.1 was effectively inhibited by antibodies from individuals who had been vaccinated with the XFG-adapted mRNA vaccine Comirnaty, which is currently in use in Germany. In contrast, the SARS-CoV-2 variant BA.3.2, which is primarily detected in children, was only inadequately inhibited by these antibodies.

“Our results suggest that PJ.2.1 is likely spreading worldwide due to improved ACE2 binding,” says Markus Hoffmann. “We assume that the XFG-adapted vaccine provides effective protection against PJ.2.1 as well as against the XFG viruses that are also circulating - at least as long as these viruses do not acquire mutations that allow them to evade the antibody response more effectively.”

Stefan Pöhlmann adds: “Notably, neither the vaccine used last season nor the currently available vaccine elicits an antibody response that efficiently blocks BA.3.2 from entering cells. Since BA.3.2 is detected primarily in children, it should be investigated whether an additional component tailored to this variant could be included in future COVID-19 vaccines.”
Happle C, Hoffmann M, Stankov M et al. Humoral immunity after mRNA SARS-CoV-2 XFG vaccination. The Lancet Infectious Diseases, Nov. 5, 2026; DOI: 10.1016/S1473-3099(26)00569-4

Hoffmann M, Zhang L, Chen N, Moor N, Nehlmeier I, Graichen L, Moldenhauer AS, Dopfer-Jablonka A, Happle C, Behrens GMN, Pöhlmann S. Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1. J Infect. Oct 24, 2026;93(5):106886. DOI: 10.1016/j.jinf.2026.106886.
Fichiers joints
  • Prof. Dr. Stefan Pöhlmann and Dr. Markus Hoffmann, infection biologists at the German Primate Center. Photo: Karin Tilch
Regions: Europe, Germany, France, Netherlands, Spain, North America, Canada, United States
Keywords: Health, Covid-19

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement